Skip to main content

Treatment Clinical Trials for Small Cell Lung Cancer

Review the small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 95

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Status: Active
Location: 4 locations
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Status: Active
Location: 2 locations
Tarlatamab in Combination with Standard of Care Radiation Therapy for the Treatment of Relapsed or Refractory of DLL3-Expressing Small Cell Lung Cancers and other High Grade Neuroendocrine Cancers
Status: Active
Location: 2 locations
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Status: Active
Location: 2 locations
Valemetostat and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer
Status: Active
Location: 2 locations
Accelerated radiation (HART) for the Treatment of Patients with Lung Cancer Receiving Chemotherapy
Status: Active
Location: 2 locations
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Status: Active
Location: 2 locations
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Lamivudine in Combination with Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Status: Active
Location: 4 locations
Pembrolizumab after Radiation Therapy and Chemotherapy in Treating Patients with Limited Stage Small Cell Lung Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Testing the Effect of an Anticancer Drug, Onvansertib, in Advanced-Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Fingolimod for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Total Body Irradiation and Hypofractionated Radiation Therapy with Atezolizumab and Chemotherapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, TESSERACT Trial
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Cirtuvivint and Irinotecan for the Treatment of Relapsed Small Cell Lung Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Genetically Modified Immune Cells (iC9-GD2.CAR.IL-15 T Cells) for the Treatment of Extensive Stage Small Cell Lung Cancer or Stage IV Non-small Cell Lung Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Iadademstat and Atezolizumab with SBRT for the Treatment of Persistent, Recurrent, or Progressive Extensive Stage Small-Cell Lung Cancer
Status: Active
Location: Yale University, New Haven, Connecticut
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Status: Active
Location: 2 locations
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland